Voloridge Investment Management
ARQT icon

Voloridge Investment Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Voloridge Investment Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.13M Sell
157,429
-383,082
-71% -$8.92M 0.02% 569
2026
Q1 		$12.7M Sell
540,511
-373,509
-41% -$9.53M 0.05% 445
2025
Q4 		$26.5M Buy
914,020
+80,530
+10% +$2.06M 0.09% 273
2025
Q3 		$15.7M Buy
+833,490
New +$13.1M 0.05% 419
2025
Q2 		– Sell
-77,035
Closed -$1.2M – 1157
2025
Q1 		$1.2M Sell
77,035
-213,903
-74% -$3.01M ﹤0.01% 1023
2024
Q4 		$4.05M Buy
290,938
+162,495
+127% +$1.78M 0.01% 825
2024
Q3 		$1.19M Sell
128,443
-434,728
-77% -$4.29M ﹤0.01% 1007
2024
Q2 		$5.24M Sell
563,171
-380,296
-40% -$3.44M 0.02% 735
2024
Q1 		$9.35M Buy
+943,467
New +$7.04M 0.03% 503

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Voloridge Investment Management's ARQT Position: Q2 2026 in Review

Voloridge Investment Management reduced its Arcutis Biotherapeutics (ARQT) stake by 71% in Q2 2026, selling an estimated $8.92M and leaving 157,429 shares worth $4.13M. The position accounts for 0.02% of the portfolio, ranked #569.

Voloridge Investment Management first reported a position in ARQT in Q1 2024 and has held it in 9 quarters since. The position peaked at $26.5M in Q4 2025. 273 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Voloridge Investment Management held 157,429 shares of Arcutis Biotherapeutics worth $4.13M as of Q2 2026.
  • Voloridge Investment Management sold 383,082 Arcutis Biotherapeutics shares in Q2 2026, an estimated $8.92M.
  • Arcutis Biotherapeutics made up 0.02% of Voloridge Investment Management's portfolio in Q2 2026, its #569 holding.
  • Voloridge Investment Management first reported a position in Arcutis Biotherapeutics in Q1 2024 and has held it in 9 quarters since.
  • Voloridge Investment Management's Arcutis Biotherapeutics position peaked at $26.5M in Q4 2025.
  • 273 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Voloridge Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.